

Seong Mi Moon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8888239/publications.pdf>

Version: 2024-02-01

44
papers

1,308
citations

471509

17
h-index

361022

35
g-index

45
all docs

45
docs citations

45
times ranked

1279
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0202721.	3.2	4
2	Comparative Study on the Effect of Cidofovir Treatment for Severe Adenovirus Pneumonia. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1436-1442.	2.8	8
3	Translation and validation of the Korean version of the clinical frailty scale in older patients. <i>BMC Geriatrics</i> , 2021, 21, 47.	2.7	10
4	Clinical impact of forced vital capacity on exercise performance in patients with chronic obstructive pulmonary disease. <i>Journal of Thoracic Disease</i> , 2021, 13, 837-846.	1.4	3
5	Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates. <i>Scientific Reports</i> , 2021, 11, 6108.	3.3	24
6	Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. <i>European Respiratory Journal</i> , 2020, 55, 1900798.	6.7	89
7	Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 3435-3444.	1.1	9
8	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. <i>Scientific Reports</i> , 2020, 10, 3178.	3.3	19
9	Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	10
10	<i>In Vitro</i> Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	44
11	Species Distribution and Macrolide Susceptibility of <i>Mycobacterium fortuitum</i> Complex Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
12	Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. <i>European Respiratory Journal</i> , 2019, 53, 1801636.	6.7	6
13	Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. <i>Respiratory Medicine</i> , 2019, 151, 1-7.	2.9	38
14	Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016. <i>Emerging Infectious Diseases</i> , 2019, 25, 569-572.	4.3	113
15	Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. <i>Respiratory Medicine</i> , 2019, 148, 37-42.	2.9	12
16	Computed tomographic findings of macrolide-resistant Mycobacterium massiliense pulmonary disease and changes after antibiotic treatment. <i>Medicine (United States)</i> , 2019, 98, e16826.	1.0	0
17	Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 107-111.	1.8	29
18	Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 38-40.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Diagnostic Performance of Radial Probe Endobronchial Ultrasound without a Guide-Sheath and the Feasibility of Molecular Analysis. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 319.	1.8	18
20	Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	41
21	Differences in drug susceptibility pattern between <i>Mycobacterium avium</i> and <i>Mycobacterium intracellulare</i> isolated in respiratory specimens. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 315-318.	1.7	35
22	Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
23	Non-intubated video-assisted thoracoscopic lung biopsy for interstitial lung disease: a single-center experience. <i>Journal of Thoracic Disease</i> , 2018, 10, 3262-3268.	1.4	17
24	Mutations in <i>gyrA</i> and <i>gyrB</i> in Moxifloxacin-Resistant <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> Complex Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
25	Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015. <i>Journal of Korean Medical Science</i> , 2018, 33, e65.	2.5	52
26	Development of Macrolide Resistance and Reinfection in Refractory <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1322-1330.	5.6	46
27	Effect of a 150Âmg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and <i>Mycobacterium avium</i> complex lung disease. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 658-660.	1.7	5
28	Distribution and clinical significance of <i>Mycobacterium avium</i> complex species isolated from respiratory specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 125-137.	1.8	39
29	Clofazimine-Containing Regimen for the Treatment of <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	86
30	Outcomes of <i>Mycobacterium avium</i> complex lung disease based on clinical phenotype. <i>European Respiratory Journal</i> , 2017, 50, 1602503.	6.7	154
31	Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection. <i>Lung Cancer</i> , 2017, 111, 69-74.	2.0	13
32	Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication. <i>PLoS ONE</i> , 2017, 12, e0169775.	2.5	12
33	Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. <i>International Journal of COPD</i> , 2016, Volume 11, 1857-1865.	2.3	17
34	Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 55-58.	2.2	3
35	Lung cancer with superior vena cava syndrome diagnosed by intravascular biopsy using EBUS-TBNA. <i>Respiratory Medicine Case Reports</i> , 2016, 19, 177-180.	0.4	3
36	Clinical characteristics and treatment outcomes of pulmonary disease caused by <i>Mycobacterium chimaera</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 382-384.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Peak Plasma Concentration of Azithromycin and Treatment Responses in <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6076-6083.	3.2	43
38	Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6758-6765.	3.2	90
39	Prolonged Maintenance of VV ECMO for 104 Days with Native Lung Recovery in Acute Respiratory Failure. <i>ASAIO Journal</i> , 2016, 62, e15-e17.	1.6	15
40	Nontuberculous Mycobacterial Lung Disease Caused by <i>Mycobacterium shinjukuense</i> : The First Reported Case in Korea. <i>Tuberculosis and Respiratory Diseases</i> , 2015, 78, 416.	1.8	5
41	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. <i>Blood Research</i> , 2015, 50, 254.	1.3	60
42	Clinical Significance of <i>Mycobacterium kansasii</i> Isolates from Respiratory Specimens. <i>PLoS ONE</i> , 2015, 10, e0139621.	2.5	38
43	Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 663-665.	3.2	15
44	Purpura fulminans on the nose with septic abortion. <i>Intensive Care Medicine</i> , 2015, 41, 1122-1122.	8.2	3